datamatters24/research-document-archive huggingface dataset:
160 
of items or services under the terms and 
conditions of the plan or coverage, and 
‘‘(B) such failure is a proximate cause of 
personal injury to, or the death of, the partici-
pant or beneficiary, 
such plan, plan sponsor, or issuer shall be liable to 
the participant or beneficiary (or the estate of such 
participant or beneficiary) for economic and non-
economic damages (but not exemplary or punitive 
damages) in connection with such personal injury or 
death. 
‘‘(2) CAUSE
OF
ACTION
MUST
NOT
INVOLVE 
MEDICALLY REVIEWABLE DECISION.— 
‘‘(A) IN GENERAL.—A cause of action is 
established under paragraph (1)(A) only if the 
decision referred to in paragraph (1)(A) does 
not include a medically reviewable decision. 
‘‘(B) 
MEDICALLY
REVIEWABLE
DECI-
SION.—For purposes of this subsection, the 
term ‘medically reviewable decision’ means a de-
nial of a claim for benefits under the plan 
which is described in section 104(d)(2) of the 
Patients’ Bill of Rights Act of 2005 (relating to 
medically reviewable decisions).
161 
‘‘(3) LIMITATION REGARDING CERTAIN TYPES 
OF ACTIONS SAVED FROM PREEMPTION OF STATE 
LAW.—A cause of action is not established under 
paragraph (1)(A) in connection with a failure de-
scribed in paragraph (1)(A) to the extent that a 
cause of action under State law (as defined in sec-
tion 514(c)) for such failure would not be preempted 
under section 514. 
‘‘(4) DEFINITIONS AND RELATED RULES.—For 
purposes of this subsection.— 
‘‘(A) ORDINARY
CARE.—The term ‘ordi-
nary care’ means, with respect to a determina-
tion on a claim for benefits, that degree of care, 
skill, and diligence that a reasonable and pru-
dent individual would exercise in making a fair 
determination on a claim for benefits of like 
kind to the claims involved. 
‘‘(B) PERSONAL INJURY.—The term ‘per-
sonal injury’ means a physical injury and in-
cludes an injury arising out of the treatment 
(or failure to treat) a mental illness or disease. 
‘‘(C) CLAIM FOR BENEFITS; DENIAL.—The 
terms ‘claim for benefits’ and ‘denial of a claim 
for benefits’ have the meanings provided such
162 
terms in section 102(e) of the Patients’ Bill of 
Rights Act of 2005. 
‘‘(D) TERMS AND CONDITIONS.—The term 
‘terms and conditions’ includes, with respect to 
a group health plan or health insurance cov-
erage, requirements imposed under title I of the 
Patients’ Bill of Rights Act of 2005. 
‘‘(E) TREATMENT
OF
EXCEPTED
BENE-
FITS.—Under section 154(a) of the Patients’ 
Bill of Rights Act of 2005, the provisions of 
this subsection and subsection (a)(1)(C) do not 
apply to certain excepted benefits. 
‘‘(5) EXCLUSION OF EMPLOYERS AND OTHER 
PLAN SPONSORS.— 
‘‘(A) CAUSES
OF
ACTION
AGAINST
EM-
PLOYERS AND PLAN SPONSORS PRECLUDED.— 
Subject to subparagraph (B), paragraph (1)(A) 
does not authorize a cause of action against an 
employer or other plan sponsor maintaining the 
plan (or against an employee of such an em-
ployer or sponsor acting within the scope of em-
ployment). 
‘‘(B) CERTAIN
CAUSES
OF
ACTION
PER-
MITTED.—Notwithstanding subparagraph (A), 
a cause of action may arise against an employer
I 
109TH CONGRESS 
1ST SESSION H. R. 1910 
To suspend temporarily the duty on Resmethrin. 
IN THE HOUSE OF REPRESENTATIVES 
APRIL 27, 2005 
Mr. ETHERIDGE introduced the following bill; which was referred to the 
Committee on Ways and Means 
A BILL 
To suspend temporarily the duty on Resmethrin. 
Be it enacted by the Senate and House of Representa-
tives of the United States of America in Congress assembled, 
SECTION 1. RESMETHRIN. 
(a) IN GENERAL.—Subchapter II of chapter 99 of 
the Harmonized Tariff Schedule of the United States is 
amended by inserting in numerical sequence the following: 
‘‘ 
9902.04.42 
[5-(Phenylmethyl)–3- 
furanyl]methyl 2,2-dimethyl- 
3-(2-methyl-1-pro-
pe-
nyl)cyclopropanecarboxylate 
(Resmethrin) (CAS No. 
10453–86–8) (provided for 
in subheading 2932.19.10) ..
Free 
No change 
No change 
On or before 
12/31/2008 
’’. 
(b) EFFECTIVE DATE.—The amendment made by 
subsection (a) applies to goods entered, or withdrawn from
warehouse for consumption, on or after the 15th day after 
the date of the enactment of this Act. 
Æ
I 
109TH CONGRESS 
1ST SESSION H. R. 1911 
To reduce temporarily the duty on Clothianidin. 
IN THE HOUSE OF REPRESENTATIVES 
APRIL 27, 2005 
Mr. ETHERIDGE introduced the following bill; which was referred to the 
Committee on Ways and Means 
A BILL 
To reduce temporarily the duty on Clothianidin. 
Be it enacted by the Senate and House of Representa-
tives of the United States of America in Congress assembled, 
SECTION 1. CLOTHIANIDIN. 
(a) IN GENERAL.—Subchapter II of chapter 99 of 
the Harmonized Tariff Schedule of the United States is 
amended by inserting in numerical sequence the following 
new heading: 
‘‘ 
9902.05.52 
(E)–1-(2-Chloro-1,3-thiazol- 
5-ylmethyl)–3-methyl-2- 
nitroguanidine (Clothianidin) 
(CAS No. 210880–92–5) 
(provided for in subheading 
2934.10.90) .........................
5.4% 
No change 
No change 
On or before 
12/31/2009 
’’.
(b) EFFECTIVE DATE.—The amendment made by 
subsection (a) applies to goods entered, or withdrawn from 
warehouse for consumption, on or after the 15th day after 
the date of the enactment of this Act. 
Æ
I 
109TH CONGRESS 
1ST SESSION H. R. 2165 
To extend the duty suspension on Menthyl anthranilate. 
IN THE HOUSE OF REPRESENTATIVES 
MAY 5, 2005 
Mr. BROWN of South Carolina introduced the following bill; which was 
referred to the Committee on Ways and Means 
A BILL 
To extend the duty suspension on Menthyl anthranilate. 
Be it enacted by the Senate and House of Representa-
tives of the United States of America in Congress assembled, 
SECTION 1. MENTHYL ANTHRANILATE. 
(a) IN GENERAL.—Heading 9902.01.40 of the Har-
monized Tariff Schedule of the United States (relating to 
Menthyl anthranilate) is amended by striking ‘‘12/31/ 
2006’’ and inserting ‘‘12/31/2008’’. 
(b) EFFECTIVE DATE.—The amendment made by 
subsection (a) applies to goods entered, or withdrawn from 
warehouse for consumption, on or after the 15th day after 
the date of the enactment of this Act. 
Æ
163 
or other plan sponsor (or against an employee 
of such an employer or sponsor acting within 
the scope of employment) under paragraph 
(1)(A), to the extent there was direct participa-
tion by the employer or other plan sponsor (or 
employee) in the decision of the plan under sec-
tion 102 of the Patients’ Bill of Rights Act of 
2005 upon consideration of a claim for benefits 
or under section 103 of such Act upon review 
of a denial of a claim for benefits. 
‘‘(C) DIRECT PARTICIPATION.— 
‘‘(i) IN
GENERAL.—For purposes of 
subparagraph (B), the term ‘direct partici-
pation’ means, in connection with a deci-
sion described in paragraph (1)(A), the ac-
tual making of such decision or the actual 
exercise of control in making such decision. 
‘‘(ii) RULES OF CONSTRUCTION.—For 
purposes of clause (i), the employer or plan 
sponsor (or employee) shall not be con-
strued to be engaged in direct participation 
because of any form of decisionmaking or 
other conduct that is merely collateral or 
precedent to the decision described in 
paragraph (1)(A) on a particular claim for
164 
benefits of a participant or beneficiary, in-
cluding (but not limited to)— 
‘‘(I) any participation by the em-
ployer or other plan sponsor (or em-
ployee) in the selection of the group 
health plan or health insurance cov-
erage involved or the third party ad-
ministrator or other agent; 
‘‘(II) any engagement by the em-
ployer or other plan sponsor (or em-
ployee) in any cost-benefit analysis 
undertaken in connection with the se-
lection of, or continued maintenance 
of, the plan or coverage involved; 
‘‘(III) any participation by the 
employer or other plan sponsor (or 
employee) in the process of creating, 
continuing, modifying, or terminating 
the plan or any benefit under the 
plan, if such process was not substan-
tially focused solely on the particular 
situation of the participant or bene-
ficiary 
referred 
to 
in 
paragraph 
(1)(A); and
165 
‘‘(IV) any participation by the 
employer or other plan sponsor (or 
employee) in the design of any benefit 
under the plan, including the amount 
of copayment and limits connected 
with such benefit. 
‘‘(iii) IRRELEVANCE OF CERTAIN COL-
LATERAL
EFFORTS
MADE
BY
EMPLOYER 
OR PLAN SPONSOR.—For purposes of this 
subparagraph, an employer or plan sponsor 
shall not be treated as engaged in direct 
participation in a decision with respect to 
any claim for benefits or denial thereof in 
the case of any particular participant or 
beneficiary solely by reason of— 
‘‘(I) any efforts that may have 
been made by the employer or plan 
sponsor to advocate for authorization 
of coverage for that or any other par-
ticipant or beneficiary (or any group 
of participants or beneficiaries), or 
‘‘(II) any provision that may 
have been made by the employer or 
plan sponsor for benefits which are 
not covered under the terms and con-
I 
109TH CONGRESS 
1ST SESSION H. R. 2166 
To suspend temporarily the duty on Frescolat MGA. 
IN THE HOUSE OF REPRESENTATIVES 
MAY 5, 2005 
Mr. BROWN of South Carolina introduced the following bill; which was 
referred to the Committee on Ways and Means 
A BILL 
To suspend temporarily the duty on Frescolat MGA. 
Be it enacted by the Senate and House of Representa-
tives of the United States of America in Congress assembled, 
SECTION 1. FRESCOLAT MGA. 
(a) IN GENERAL.—Subchapter II of chapter 99 of 
the Harmonized Tariff Schedule of the United States is 
amended by inserting in numerical sequence the following: 
‘‘ 
9902.06.41 
Menthone Glycerin Acetal 
(CAS No. 63187–91–7) 
(provided for in subheading 
2932.99.90) .........................
Free 
No change 
No change 
On or before 
12/31/2008 
’’. 
(b) EFFECTIVE DATE.—The amendment made by 
subsection (a) applies to goods entered, or withdrawn from
(1) Section 203(c) of the Immigration and Na-
tionality Act (8 U.S.C. 1153(c), and any other provi-
sion of law authorizing the issuance of diversity im-
migrant visas, is repealed. 
(2) Personal interviews are mandatory for ad-
mission of aliens to the United States under section 
217 of the Immigration and Nationality Act (8 
U.S.C. 1187). 
(3) The Secretary, with the Secretary of State, 
verifies that each alien admitted on the basis of a 
nonimmigrant visa has had a personal interview with 
a consular officer prior to the issuance of the visa. 
(d) CONSTRUCTION.—During any period in which a 
waiver granted under subsection (c) applies to aliens 
barred from receipt of nonimmigrant visas under section 
7(a)(2), the bar shall supersede the waiver. 
SEC. 12. TEMPORARY FUNDING FOR DETENTION AND RE-
MOVAL ASSISTANCE PROVIDED BY STATE 
AND LOCAL LAW ENFORCEMENT AGENCIES. 
The Secretary of Homeland Security shall reimburse 
verifiable claims submitted by a law enforcement agency 
of a State, or any political subdivision of a State, that 
were lawfully incurred for the emergency medical care, 
housing, and care in a secure facility, and the transpor-
tation into Federal custody at a location designated by the
Secretary, of any alien detained as inadmissible under sec-
tion 212(a) of the Immigration and Nationality Act (8 
U.S.C. 1182(a)) or deportable under section 237(a) of 
such Act (8 U.S.C. 1227(a)), if— 
(1) transfer to Federal custody has occurred; 
(2)(A) a determination is subsequently made 
under section 240(c)(1) of the Immigration and Na-
tionality Act (8 U.S.C. 1229a(c)(1)) that such alien 
is removable; or 
(B) a determination is made that the alien has 
permanently departed the United States; 
(3) reimbursement for all costs excepting trans-
portation costs is made according to a per diem rate 
established by the Secretary; and 
(4) the first day of such detention is not later 
than the date on which the certification described in 
section 9 is made. 
SEC. 13. EFFECTIVE DATE. 
This Act shall take effect in each local time zone upon 
the commencement in such zone of the first Sunday that 
occurs two weeks after the date of the enactment of this 
Act. 
Æ
166 
ditions of the plan for that or any 
other participant or beneficiary (or 
any group of participants or bene-
ficiaries). 
‘‘(D) APPLICATION TO CERTAIN PLANS.— 
‘‘(i) IN
GENERAL.—Notwithstanding 
any other provision of this subsection, no 
group health plan described in clause (ii) 
(or plan sponsor of such a plan) shall be 
liable under paragraph (1) for the perform-
ance of, or the failure to perform, any non- 
medically reviewable duty under the plan. 
‘‘(ii) DEFINITION.—A group health 
plan described in this clause is— 
‘‘(I) a group health plan that is 
self-insured and self administered by 
an employer (including an employee of 
such an employer acting within the 
scope of employment); or 
‘‘(II) a multiemployer plan as de-
fined in section 3(37)(A) (including 
an employee of a contributing em-
ployer or of the plan, or a fiduciary of 
the plan, acting within the scope of 
employment or fiduciary responsi-
167 
bility) that is self-insured and self-ad-
ministered. 
‘‘(6) EXCLUSION OF PHYSICIANS AND OTHER 
HEALTH CARE PROFESSIONALS.— 
‘‘(A) IN GENERAL.—No treating physician 
or other treating health care professional of the 
participant or beneficiary, and no person acting 
under the direction of such a physician or 
health care professional, shall be liable under 
paragraph (1) for the performance of, or the 
failure to perform, any non-medically reviewable 
duty of the plan, the plan sponsor, or any 
health insurance issuer offering health insur-
ance coverage in connection with the plan. 
‘‘(B) DEFINITIONS.—For purposes of sub-
paragraph (A)— 
‘‘(i) HEALTH CARE PROFESSIONAL.— 
The term ‘health care professional’ means 
an individual who is licensed, accredited, or 
certified under State law to provide speci-
fied health care services and who is oper-
ating within the scope of such licensure, 
accreditation, or certification. 
‘‘(ii) NON-MEDICALLY
REVIEWABLE 
DUTY.—The term ‘non-medically review-
I 
109TH CONGRESS 
1ST SESSION H. R. 1913 
To suspend temporarily the duty on ACRYPET UT100. 
IN THE HOUSE OF REPRESENTATIVES 
APRIL 27, 2005 
Mr. HOBSON introduced the following bill; which was referred to the 
Committee on Ways and Means 
A BILL 
To suspend temporarily the duty on ACRYPET UT100. 
Be it enacted by the Senate and House of Representa-
tives of the United States of America in Congress assembled, 
SECTION 1. SUSPENSION OF DUTY ON ACRYPET UT100. 
(a) IN GENERAL.—Subchapter II of chapter 99 of 
the Harmonized Tariff Schedule of the United States is 
amended by inserting in numerical sequence the following 
new heading: 
‘‘ 
9902.--.- 
2-Propenoic acid, 2-methyl-, 
methyl ester, polymer with 
1-cyclohexyl-1H-pyrrole-2,5- 
dione,ethylbenzene and (1- 
methylethenyl)benzene (CAS 
No. 107194–09–2) (provided 
for in subheading 
3906.10.00) .........................
Free 
No change 
No change 
On or before 
12/31/2009. 
.’’
HR 1913 IH 
(b) EFFECTIVE DATE.—The amendment made by 
subsection (a) applies to articles entered, or withdrawn 
from warehouse for consumption, on or after the 15th day 
after the date of the enactment of this Act. 
Æ
168 
able duty’ means a duty the discharge of 
which does not include the making of a 
medically reviewable decision. 
‘‘(7) EXCLUSION OF HOSPITALS.—No treating 
hospital of the participant or beneficiary shall be lia-
ble under paragraph (1) for the performance of, or 
the failure to perform, any non-medically reviewable 
duty (as defined in paragraph (6)(B)(ii)) of the 
plan, the plan sponsor, or any health insurance 
issuer offering health insurance coverage in connec-
tion with the plan. 
‘‘(8) RULE
OF
CONSTRUCTION
RELATING
TO 
EXCLUSION
FROM
LIABILITY
OF
PHYSICIANS, 
HEALTH CARE PROFESSIONALS, AND HOSPITALS.— 
Nothing in paragraph (6) or (7) shall be construed 
to limit the liability (whether direct or vicarious) of 
the plan, the plan sponsor, or any health insurance 
issuer offering health insurance coverage in connec-
tion with the plan. 
‘‘(9) REQUIREMENT OF EXHAUSTION.— 
‘‘(A) IN GENERAL.—A cause of action may 
not be brought under paragraph (1) in connec-
tion with any denial of a claim for benefits of 
any individual until all administrative processes 
under sections 102 and 103 of the Patients’
169 
Bill of Rights Act of 2005 (if applicable) have 
been exhausted. 
‘‘(B) EXCEPTION FOR NEEDED CARE.—A 
participant or beneficiary may seek relief exclu-
sively in Federal court under subsection 
502(a)(1)(B) prior to the exhaustion of admin-
istrative remedies under sections 102, 103, or 
104 of the Patients’ Bill of Rights Act of 2005 
(as required under subparagraph (A)) if it is 
demonstrated to the court that the exhaustion 
of such remedies would cause irreparable harm 
to the health of the participant or beneficiary. 
Notwithstanding the awarding of relief under 
subsection 502(a)(1)(B) pursuant to this sub-
paragraph, no relief shall be available as a re-
sult of, or arising under, paragraph (1)(A) or 
paragraph (10)(B), with respect to a partici-
pant or beneficiary, unless the requirements of 
subparagraph (A) are met. 
‘‘(C) RECEIPT OF BENEFITS DURING AP-
PEALS PROCESS.—Receipt by the participant or 
beneficiary of the benefits involved in the claim 
for benefits during the pendency of any admin-
istrative processes referred to in subparagraph
170 
(A) or of any action commenced under this sub-
section— 
‘‘(i) shall not preclude continuation of 
all such administrative processes to their 
conclusion if so moved by any party, and 
‘‘(ii) shall not preclude any liability 
under subsection (a)(1)(C) and this sub-
section in connection with such claim. 
The court in any action commenced under this 
subsection shall take into account any receipt of 
benefits during such administrative processes or 
such action in determining the amount of the 
damages awarded. 
‘‘(D) 
ADMISSIBLE.—Any 
determination 
made by a reviewer in an administrative pro-
ceeding under section 103 of the Patients’ Bill 
of Rights Act of 2005 shall be admissible in 
any Federal court proceeding and shall be pre-
sented to the trier of fact. 
‘‘(10) STATUTORY DAMAGES.— 
‘‘(A) IN
GENERAL.—The remedies set 
forth in this subsection (n) shall be the exclu-
sive remedies for causes of action brought 
under this subsection.
I 
109TH CONGRESS 
1ST SESSION H. R. 1914 
To amend the Harmonized Tariff Schedule of the United States to provide 
that the calculation of the duty imposed on imported cherries that are 
provisionally preserved does not include the weight of the preservative 
materials of the cherries. 
IN THE HOUSE OF REPRESENTATIVES 
APRIL 27, 2005 
Mr. HONDA introduced the following bill; which was referred to the Committee 
on Ways and Means 
A BILL 
To amend the Harmonized Tariff Schedule of the United 
States to provide that the calculation of the duty imposed 
on imported cherries that are provisionally preserved does 
not include the weight of the preservative materials of 
the cherries. 
Be it enacted by the Senate and House of Representa-
tives of the United States of America in Congress assembled,
SECTION 1. MODIFICATION OF CALCULATION OF DUTY IM-
POSED ON IMPORTED CHERRIES THAT ARE 
PROVISIONALLY PRESERVED. 
(a) AMENDMENTS.—Subheading 0812.10.00 of the 
Harmonized Tariff Schedule of the United States is 
amended— 
(1) in the general subcolumn of the column 1 
rate of duty, by inserting ‘‘on drained weight’’ after 
‘‘13.4¢/kg’’; and 
(2) in the special subcolumn of the column 1 
rate of duty, by inserting ‘‘on drained weight’’ after 
‘‘10¢/kg’’ and ‘‘12¢/kg’’. 
(b) EFFECTIVE DATE.—The amendments made by 
subsection (a) shall be effective for the period beginning 
on the date of the enactment of this Act and ending on 
the date on which the specific rate of duty involved is re-
duced to free. 
Æ
I 
109TH CONGRESS 
1ST SESSION H. R. 2167 
To extend the duty suspension on o-tert-Butylcyclohexanol. 
IN THE HOUSE OF REPRESENTATIVES 
MAY 5, 2005 
Mr. BROWN of South Carolina introduced the following bill; which was 
referred to the Committee on Ways and Means 
A BILL 
To extend the duty suspension on o-tert-Butylcyclohexanol. 
Be it enacted by the Senate and House of Representa-
tives of the United States of America in Congress assembled, 
SECTION 1. O-TERT-BUTYLCYCLOHEXANOL. 
(a) IN GENERAL.—Heading 9902.05.02 of the Har-
monized Tariff Schedule of the United States (relating to 
o-tert-Butylcyclohexanol) is amended by striking ‘‘12/31/ 
2006’’ and inserting ‘‘12/31/2008’’. 
(b) EFFECTIVE DATE.—The amendment made by 
subsection (a) applies to goods entered, or withdrawn from 
warehouse for consumption, on or after the 15th day after 
the date of the enactment of this Act. 
Æ
I 
109TH CONGRESS 
1ST SESSION H. R. 2168 
To extend the duty suspension on 5-Methyl-2-(methylethyl)cyclohexyl-2- 
hydroxypropanoate. 
IN THE HOUSE OF REPRESENTATIVES 
MAY 5, 2005 
Mr. BROWN of South Carolina introduced the following bill; which was 
referred to the Committee on Ways and Means 
A BILL 
To extend the duty suspension on 5-Methyl-2- 
(methylethyl)cyclohexyl-2-hydroxypropanoate. 
Be it enacted by the Senate and House of Representa-
tives of the United States of America in Congress assembled, 
SECTION 
1. 
5-METHYL-2-(METHYLETHYL)CYCLOHEXYL-2- 
HYDROXYPROPANOATE. 
(a) IN GENERAL.—Heading 9902.01.42 of the Har-
monized Tariff Schedule of the United States (relating to 
5-Methyl-2-(methylethyl)cyclohexyl-2-hydroxypropanoate) 
is amended by striking ‘‘12/31/2006’’ and inserting ‘‘12/ 
31/2008’’.
(b) EFFECTIVE DATE.—The amendment made by 
subsection (a) applies to goods entered, or withdrawn from 
warehouse for consumption, on or after the 15th day after 
the date of the enactment of this Act. 
Æ
137 
with representatives of that labor organization shall sat-
isfy the consultation requirement in paragraph (1). 
‘‘(B) In the case of employees other than employees 
referred to in subparagraph (A), consultation with appro-
priate representatives of those employees shall satisfy the 
consultation requirement in paragraph (1). 
‘‘(C) The head of each executive agency shall pre-
scribe regulations to carry out this subsection. The regula-
tions shall include provisions for the selection or designa-
tion of appropriate representatives of employees referred 
to in paragraph (2)(B) for purposes of consultation re-
quired by paragraph (1). 
‘‘(c) CONGRESSIONAL NOTIFICATION.—(1) Before 
commencing a public-private competition under subsection 
(a), the head of an executive agency shall submit to Con-
gress a report containing the following: 
‘‘(A) The function for which such public-private 
competition is to be conducted. 
‘‘(B) The location at which the function is per-
formed by agency civilian employees. 
‘‘(C) The number of agency civilian employee 
positions potentially affected. 
‘‘(D) The anticipated length and cost of the 
public-private competition, and a specific identifica-
tion of the budgetary line item from which funds will
I 
109TH CONGRESS 
1ST SESSION H. R. 1915 
To reduce temporarily the duty on diethyl ketone. 
IN THE HOUSE OF REPRESENTATIVES 
APRIL 27, 2005 
Mr. HULSHOF introduced the following bill; which was referred to the 
Committee on Ways and Means 
A BILL 
To reduce temporarily the duty on diethyl ketone. 
Be it enacted by the Senate and House of Representa-
tives of the United States of America in Congress assembled, 
SECTION 1. DIETHYL KETONE. 
(a) IN GENERAL.—Subchapter II of chapter 99 of 
the Harmonized Tariff Schedule of the United States is 
amended by inserting in numerical sequence the following 
new heading: 
‘‘ 
9902.05.60 
Diethyl ketone (CAS No. 
96–22–0) (provided for in 
subheading 2914.19.00) ......
2.7% 
No change 
No change 
On or before 
12/31/2008 
’’. 
(b) EFFECTIVE DATE.—The amendment made by 
subsection (a) applies to goods entered, or withdrawn from
warehouse for consumption, on or after the 15th day after 
the date of enactment of this Act. 
Æ